HEC88473

'''HEC88473''' is an experimental dual GLP-1 and fibroblast growth factor 21 (FGF21) receptor agonist. It is developed by the Chinese company HEC Pharm for diabetes and non-alcoholic steatohepatitis.<ref>{{cite journal |last1=Pan |first1=Qi |last2=Lin |first2=Shushan |last3=Li |first3=Yu |last4=Liu |first4=Liang |last5=Li |first5=Xiaoping |last6=Gao |first6=Xianglei |last7=Yan |first7=Jiangyu |last8=Gu |first8=Baohua |last9=Chen |first9=Xiaofeng |last10=Li |first10=Wenjia |last11=Tang |first11=Xinfa |last12=Chen |first12=Chao |last13=Guo |first13=Lixin |title=A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis |journal=eBioMedicine |date=January 2021 |volume=63 |article-number=103202 |doi=10.1016/j.ebiom.2020.103202 |issn=2352-3964|doi-access=free |pmid=33421947 |pmc=7806870 }}</ref><ref>{{cite journal |last1=Negi |first1=Chander K. |last2=Babica |first2=Pavel |last3=Bajard |first3=Lola |last4=Bienertova-Vasku |first4=Julie |last5=Tarantino |first5=Giovanni |title=Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease |journal=Metabolism |date=January 2022 |volume=126 |article-number=154925 |doi=10.1016/j.metabol.2021.154925|doi-access=free |pmid=34740573 }}</ref>

==References== {{reflist}}

Category:GLP-1 receptor agonists Category:Experimental diabetes drugs Category:Peptide therapeutics